The concordance ratios of KRAS sequences were 11/12 and 5/12 (p = 0.03) between EBC and cancer tissue, and blood and cancer tissue, respectively, in the subgroup of 12 KRAS-mutation positive NSCLC patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.